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Leukaemia mortality around French nuclear sites
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S_qy This study was designed to investigate leukaemia mortality in the population under the age of 25
residing around the 13 French nuclear sites operating in 1985. In four eogaphical zones defined according to
the distance from the site, 503 exposed communes were identified and followed up betwen 1968 and 1989. A
total of 4 132 000 person-years of observation were accumulated. The number of Icukaia deaths observed
(69) did not differ from the expected number (86.15) estimated accordig to national mortality statistics. There
was no diffrence in the risks of IeukaeMia mortality according to sex, age, type of installation and no trend
with an increasing distance from installations.
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No excess in leukaemia mortality has been observed in the
population under the age of 25 living near nuclear installa-
tions operating in 1975 in France (Hill and Laplanche, 1990),
unlike that observed in the UK (Gardner and Winter, 1984;
Forman et al., 1987; Cook-Mozaffari et al., 1989). We have
extended the previous study to include seven additional
nuclear sites, which started operating between 1975 and 1985,
and added mortality data for 1988 and 1989, which were not
available at the time of the first study.
Material
Selection ofnuclear installations
We studied the main sites operating in 1985 (Anonymous,
undated, 1992, 1993). Figure 1 shows the 13 sites selcted,
with the year in which each installation started operating and
the nature of the activity. Next to the Tricastin site, a
uranium enrichment factory (Pierrelatte) starud operating in
the early 1960s, and is still in operation. As the main source
of pollution in the uranium enrichment factory is chemical,
this site was not studied until the Tricastin nuclear reactor
came into operation.
Selection ofthe comunes under study
Four geographical zones were defined around each installa-
tion according to the distance from the installation: <5 km,
5-10km, 10-13km and 13-16km. All the administrative
units called 'communes' located in each of these four zones
were identified for each site (Bottn des Communes, 1990). A
total of 503 communes were thus selcted, 62 in the 0-5 km
zone, 141 in the 5-10km zone, 123 in the 10-13 km zone
and 177 in the 13-161km zone.
From the Institut National de la Sante et de la Recherche
M&licale (INSERM), service commun no. 8 (French
National Institute for Health and Medical Research joint
service no. 8), we obtained the cause of each death that
ourred in the population aged 0-24 years between 1968
and 1989 by year, zone, sex and 5 year age groups. The
underlying cause of each death was coded according to the
International Clasification of Diseases (ICD), eighth revision
before 1979, and ninth revision thereafter (World Health
Organization, 1965, 1978).
Census data by commune were obtained from the Institut
National de la Statistique et des Etudes Economiques
(INSEE: French National Institute of Economic and Statis-
tical Information), for the four censuses which took place in
1968, 1975, 1982 and 1990. The population at risk was
estimated from these data for the period 1968-89.
Metods
Period wuder study
Ten sites started operating in 1968 or later. For these sites,
the study period started on 1 January of the year following
the date when it first started operating. Deaths prior to this
date, as well as the corresponding population at risk, were
not taken into account. For the three sites which started
operating before 1968, the study period began on 1 January
1968. The study period was therefore 1968-89 for these three
sites.
Number ofperson-years at risk
The census population was available by sex and 5 year age
group for each commune. The censuses provided population
figures on 1 March 1968, 20 February 1975, 4 March 1982
and 5 March 1990. We have estimated the populations on 1
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Table I Number of person-years, observed and expected number of leukaemia
deaths and standardised mortality ratios (SMR) by sex, age, type of installation and
distance from nuclear installations
Nwnber of
Person -ears leukaemia deaths
Characteristics in thousands Observed Expected SMR (95% CI}
Sex
Male 2129 36 51.30 70O (49-97)
Female 2003 33 34.85 95 (65- 133)
Age (years)
0-4 816 12 16.95 71 (37- 124)
5-9 862 15 22.16 68 (38-112)
10- 14 871 12 17.17 70 (36- 122)
15- 19 859 17 16.96 100 (58-160)
20-24 724 13 12.91 101 (54-172)
Installation
Reprocessing 1284 21 28.66 73 (45-112)
Others 2848 48 57.49 83 (62-111)
Distance (kn)
<5 460 7 9.63 73 (29-150)
5-9.9 1469 26 31.05 84 (55- 123)
10-12.9 802 8 16.20 49b (21-97)
13- 15.9 1401 28 29.27 96 (64-138)
Total 4132 69 86.15 80 (62-101)
SMR, standardised mortality ratio [SMR (%)= 100 (O/E)]. 95% CI, 95%
confidence interval. ap = 0.03 (two-sided test). bp = 0.04 (two-sided test).
January, by sex and 5 year age groups, on the assumption
that the ratio between the census population and the 1
January population was the same for each commune and
equal to the ratio calculated for the total French population.
Yearly estimates of populations on 1 January were computed
by linear interpolation between the populations on 1 January
for census years, for a given sex and age group. The popula-
tion at risk, for a given year and a given commune, is the
average of the population on 1 January of that year and of
the following year.
To test for the possible existence of an increase in
leukaemia mortality between age 0 and 24 years around
French nuclear sites, the observed (0) mortality was com-
pared with the mortality expected (E) on the basis of
national rates (Hill et al., 1989, 1993). The standardised
mortality ratios (SMR = 100 x O/E) were compared with 100
by tests assuming Poisson distribution. The heterogeneity
between installations and a possible trend in mortality with
an increasing distance from installations were also tested
(Breslow and Day, 1987). All significance tests were two-
sided.
Table H Observed and expected number of leukaemia deaths and
standardised mortality ratios (SMR) by installation (k = 1-13)
Number of leukaemia deaths
Installation Observed (Ok) Expected (Ek) Ek SMR
Blayais 0 2.37 1.90 0
Bugey 8 11.16 8.94 72
Chinon 8 8.88 7.11 90
Chooz 9 5.65 4.53 159
Cruas 3 3.30 2.64 91
Dampierre 2 2.44 1.95 82
Fessenheim 2 2.92 2.34 68
Gravelines 11 10.20 8.17 108
La Hague 2 5.36 4.29 37
Marcoule 19 23.30 18.67 81
Paluel 0 0.88 0.70 0
St-Laurent 5 6.57 5.26 76
Tricastin 0 3.12 2.50 0
Total 69 86.15 69.00 80
Ea expected number of leukaenia deaths under the assumption of
no heterogeneity between installations, E*= E. x YOt ZEk.
Results
During the period under study, a total of 4 132 000 per-
son-years of observation were accumulated in the popula-
tion aged 0-24 years residing in exposed communes. The
observed number of leukaemia (ICD8 204-207 and ICD9
204-208) deaths was 69, which was slightly less than the
86.15 deaths expected according to national mortality statis-
tics: SMR = 80 (95% confidence interval 62-101, P = 0.07).
Out of these 69 leukaemia deaths, 20 were due to lymphoid
leukaemia (ICD8 and ICD9 204), ten were due to myeloid
(ICD8 and ICD9 205) leukaemia, two were due to monocyte
leukaemia (ICD8 and ICD9 206) and 37 were due to other or
unspecified (ICD8 207 and ICD9 207-208) types of cell. The
20 observed lymphoid leukaemia deaths were compared with
the 27.10 deaths expected according to national mortality
statistics: SMR = 74 (95% confidence interval 45-114,
P = 0.20).
Table I gives the number of leukaemia deaths by sex, age,
the type of installation and the distance from the nuclear site.
Two of the 13 SMRs are significantly lower than expected;
after correction for multiple testing, there is no effect of sex
and age, no difference between reprocessing plants and reac-
tors and no linear trend with an increasing distance from the
installation.
Table II presents the number of leukaemia deaths accord-
ing to the type of installation. There was no difference in the
risk of leukaemia mortality according to the type of nuclear
site.
DEscusson
Our study shows no excess of leukaemia mortality in the
population aged 0-24 years residing around French nuclear
sites between 1968 and 1989.
Person-years were estimated by linear interpolation
between I January populations for census years, as detailed
information regarding sex, age and calendar year was not
available for the communes under study.
We used mortality rather than incidence data because
national tumour registry data are not available in France and
local registries failed to cover most of the areas studied here.
This leads to a considerable loss of power since survival from
childhood leukaemia is good and has improved during recent
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years. The ascertainment of deaths is adequate in France.
Although the ascertainment of causes of death between age 0
and 24 years could be queried to a certain extent, the regis-
tration of causes of death around nuclear sites does not differ
from that of national statistics. Because of the problem of
differential diagnosis between leukaemia and lymphoma, it
could be argued that we failed to include all leukaemia
deaths. However, when leukaemia and non-Hodgkin lym-
phoma (NHL) deaths are considered together, the results are
similar (90 observed deaths, 106.24 expected deaths). Mor-
tality from leukaemia was studied without considering the
type of leukaemia because 50% of the leukaemia death
certificates were coded 'other or unspecified type of cell'.
Our study had a 66% chance of detecting an increase of
25% and a 99% chance of detecting an increase of 50%,
with an expected number of leukaemia deaths of 86.15 and a
type I error of 5% (Breslow and Day, 1987).
Our results confirm those of a previous study (Hill and
Laplanche, 1990) and of other French studies (Dousset, 1989;
Viel and Richardson, 1990; Viel et al., 1993) and are reassur-
ing. With an increase of approximately 50% in person-years
and in leukaemia deaths, the power of the present study is
reasonable. The discrepancy with British studies remains
unexplained. Kinlen (1993) suggested that the increased
incidence of childhood leukaemia and NHL which has been
recorded close to the two British nuclear reprocessing sites of
Sellafield and Dounreay could be due to a viral infection
promoted by population mixing. This hypothesis is based on
an increased incidence of childhood leukaemia and NHL in
British new towns (Kinlen, 1988; Kinlen et al., 1990). A
study of childhood leukaemia mortality in French new towns
found no evidence of an increase in leukaemia mortality
when compared with national mortality (Laplanche and de
Vathaire, 1994). We can conclude that, if populations living
near nuclear facilities are exposed to an increased risk of
leukaemia, this excess will be below the detection limits of
such surveys.
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